Biogen Idec - 2/41

Entry	Author	Date	Location
Editor’s Picks: Xconomy Boston’s Top 20 Stories of the Third Quarter	Gregory T. Huang	10/28/11	Boston
New Genzyme CEO, Biogen Scores in 2nd MS Pill Trial, Nanotech Drug Startups Nab Funds, & More Boston-Area Life Sciences News	Erin Kutz	10/28/11	Boston
Portola Grabs $45M Upfront From Biogen Idec to Develop Autoimmune Drugs	Luke Timmerman	10/27/11	San Francisco
Biogen Idec’s Oral Multiple Sclerosis Drug Passes 2nd Major Test; Stock Soars	Luke Timmerman	10/26/11	Boston
Sha Mi, Biogen Idec’s Neurology Ace, to Join “The Genetics Institute Impact” on Dec. 14	Luke Timmerman	10/21/11	Boston
Fearless Fantasy Football, Uh, I Mean Biotech, Predictions for the Season Ahead	Luke Timmerman	09/06/11	National
Pfizer Grows in Cambridge, Repligen Eyes Imaging Approval, GI Dynamics Gets Aussie IPO, & More Boston-Area Life Sciences News	Erin Kutz	09/02/11	Boston
George Scangos, the Boy From Working Class Boston, on His Road Back to Lead Biogen Idec	Luke Timmerman	08/31/11	Boston
Verizon Buys CloudSwitch, Adimab Inks Biogen and Novo Nordisk Deals, EMD Millpore Buys Amnis, & More Boston-Area Deals News	Erin Kutz	08/31/11	Boston
Adimab Inks Collaboration Deals with Biogen Idec, Novo Nordisk	Erin Kutz	08/29/11	Boston
Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies	Luke Timmerman	08/29/11	Seattle
Verizon’s Software Beachhead in Boston: The Story Behind CloudSwitch and Terremark	Gregory T. Huang	08/26/11	Boston
Biogen Gets Euro Approval, BSX Shows Solid Q2, Alkermes Tries Again, & More Boston-Area Life Sciences News	Erin Kutz	07/29/11	Boston
Biogen Confirms Cambridge Move, Amag Merges With Allos, ACT Kicks Off Trials, & More Boston-Area Life Sciences News	Erin Kutz	07/22/11	Boston
Biogen Idec Moving HQ Back to Cambridge, Constructing Two New Buildings at Kendall Square	Luke Timmerman	07/20/11	Boston
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent	Luke Timmerman	07/18/11	National
Allozyne Looks to Rustle Up Interest on Wall Street With Backdoor IPO	Luke Timmerman	07/13/11	Seattle
Editor’s Picks: Xconomy Boston’s Top 20 Stories of the Second Quarter	Gregory T. Huang	07/01/11	Boston
Biogen Eyes Cambridge Move, Vertex Licenses Alios Drugs, Concert Nabs GSK Payment, & More Boston-Area Life Sciences News	Erin Kutz	06/24/11	Boston
Biogen Idec CEO on Move Back to Cambridge: “We’re Working on It”	Luke Timmerman	06/16/11	Boston
Vertex Gets FDA OK, Alnylam Plans For ASCO, Biogen Drug Advances in Europe, & More Boston-Area Life Sciences News	Erin Kutz	05/27/11	Boston
How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired	Luke Timmerman	05/23/11	National
Acorda Stock Soars on European Surprise	Arlene Weintraub	05/20/11	New York
Biogen Gets EU Panel OK for MS Drug	Luke Timmerman	05/20/11	Boston
Alkermes Acquires Elan Drug Manufacturing Unit for $960M	Luke Timmerman	05/09/11	Boston
My 33 Months at Xconomy, a Nano-Memoir (of Sorts)	Ryan McBride	04/29/11	Boston
SR One Opens Bay Area Shop	Ryan McBride	04/26/11	San Francisco
Biogen Shares Jump on Good News on Revenue, Oral MS Drug	Ryan McBride	04/21/11	Boston
Aveo Adds Termeer to Board, Monsanto Partners With Atlas, Biogen Drug Meets Clinical Goal, & More Boston-Area Life Sciences News	Erin Kutz	04/15/11	Boston
Biogen Idec Passes Pivotal Trial With Oral MS Drug; Shares Climb	Luke Timmerman	04/11/11	Boston
Page 2 of 14	« previous page · next page »

Entry

Author

Date

Location

Editor’s Picks: Xconomy Boston’s Top 20 Stories of the Third Quarter

10/28/11

New Genzyme CEO, Biogen Scores in 2nd MS Pill Trial, Nanotech Drug Startups Nab Funds, & More Boston-Area Life Sciences News

Erin Kutz

10/28/11

Boston

Portola Grabs $45M Upfront From Biogen Idec to Develop Autoimmune Drugs

Luke Timmerman